The Optometric Glaucoma Society would like to acknowledge the generous support of all of our sponsors

Platinum Sponsor

BAUSCH + LOMB

Gold Sponsor

aerie Pharmaceuticals, Inc.

ZEISS

Silver Sponsors

AKORN

Allergan

DIOPSYS

GLUKOS

HEIDELBERG ENGINEERING

OPTOVUE

icare VISIONARY IN VISION

www.icare-usa.com
President’s Welcome

It is a great privilege and honor to welcome you to Chicago for the 16th scientific meeting of the Optometric Glaucoma Society. We are very proud to present this year’s program showcasing some of the world’s best scientific and clinical experts in glaucoma. The OGS continues to be a model of excellence in specialty education within optometry. The relationship with the AAO continues and allows us to share a snapshot of our world class OGS scientific meeting with our colleagues from outside the OGS. This allows the OGS to share some of our world-renowned educators with those professionals attending the Academy meeting.

This is my first year as President and it is honor to be able to introduce and welcome such a stellar program and panel of renowned speakers, researchers and awardees as well as our expert members and guests. As I begin to follow in the large footprints of our past Presidents (Ben Gaddie, John Flanagan and Murray Fingeret) I am fortunate to be surrounded by OGS members who work diligently to bring this entire meeting together. My first acknowledgement is to Suresh Viswanathan whose has put today’s program together and assembled a unique integration of expert clinicians and scientists. The OGS meeting is renowned for its small meeting format that allows for intimate dialog and discussion on the most current and novel topics in glaucoma. A recurring comment from past honoree speakers is consistent praise for the interactive environment and scientific rigor of our meeting. With that, we encourage discourse with our expert presenters by commenting at one of the microphones located in the aisles.

This year we are extremely fortunate to have Dr. Robert Fechtner from SUNY Upstate Medical University, as our 2017 OGS Honoree. Dr. Fechtner’s honoree lecture is titled “Ocular Surface Disease and Topical Glaucoma Therapy”. I am also very pleased to announce this year’s President Award honoree, Dr. David Friedman, from Wilmer Eye Institute, Johns Hopkins University School of Medicine. Dr. Freidman will speak on Home IOP Monitoring and on Key Lessons from Glaucoma Clinical Trials. This packed program also includes presentations from John Berdahl, Lyne Racette, Brian Samuels, Konrad Psuedovs and OGS Ezell Fellow Jack Phu. We are grateful to all of our expert speakers responsible for this world class scientific and clinical meeting.

This meeting would not be possible without the tremendous efforts of our Meeting Committee and Industry Relations Committee. Chris Leivens is the new Chair of the IRC and has done an incredible job of furthering support for the meeting from our friends in the industry. This meeting continues to evolve at a high level due to our valued industry members and their contributions.

As the OGS Executive Director, Kellie Rogers does the vast majority of the logistics for this meeting. Her duties include: tracking all of the numerous minute details such as venue selection, catering, meeting rooms, member and guest registration, industry vendor contracting, catering, receptions, meals, awards, and speakers just to name a few. Kellie has been an asset well beyond her role in the meeting planning and now has assumed virtually all of the day to day tasks of running an organization with 125 members. As you see Kellie around the meeting, please introduce yourself and give her a big thanks.

There are other changes this year in the OGS at the Executive Board level, while Rich Madonna continues as Vice President, Danica Marrelli is now Secretary, taking over for Leo Semes who has moved over to the Optometric Glaucoma Foundation. It’s pleasure to have Danica on the Board, her contributions have already
been significant. And the new OGS Treasurer is Eric Schmidt; I greatly appreciate Eric’s guidance and oversight in this vital role. Ben Gaddie is now the Executive Vice President, following our typical succession from Presidency. I extend a big thank you to all of our members and the numerous Committee Chairs who continue to give their time and expertise to pull off this great meeting.

Thank you to everyone for entrusting me to represent this exceptional organization. Finally, please enjoy the fellowship of colleagues and friends offered at this special time of year for the OGS.

Welcome to Chicago

Michael Chaglasian, OD
OGS President

OGS Mission Statement

The Optometric Glaucoma Society (OGS) mission is to promote excellence in care of glaucoma patients through professional education and scientific investigation. The society’s major objectives are to promote education of optometrists related to all aspects of glaucoma; promote the acquisition of new knowledge about glaucoma, in part through the development of glaucoma research within optometry; facilitate the dissemination of information about glaucoma to healthcare providers and the public; and establish collaborative relationship with other related organizations.
Monday, October 9, 2017
Red Lacquer Room:
4:00 – 5:00 PM Executive Committee Meeting
5:00 – 5:30 PM General Business Meeting (for all members)
5:30 – 6:00 PM OGF Executive Committee Meeting

State Ballroom:
6:00 – 9:00 PM Opening Reception

Tuesday, October 10, 2017
State Ballroom:
7:20 – 7:50 AM Breakfast (opportunity to visit vendor exhibits)

Grand Ballroom:
7:50 AM Welcome from Michael Chaglasian, OGS President

Session 1: Early Diagnostic Characteristics and Progression Indicators in Glaucoma and Lessons from “Big Data”
Moderated by John Flanagan

8:00 – 8:15: Jack Phu (OGS Ezell Fellow): Spatial Summation in Visual Field Testing for Glaucoma: Clinical Implications
8:15 – 8:20: Discussion and questions

8:20 – 8:50: Lyne Racette: Early Detection of Glaucoma Progression Using a Novel Individualized Approach
8:50 –9:00: Discussion and questions

9:00 – 9:50: David Friedman (President’s Lecture): Big Glaucoma Clinical Trials and their Key Lessons
9:50 – 10:00: Discussion and questions

State Ballroom: 10:00 – 10:30: Morning Break (opportunity to visit vendor exhibits)

Session 2: Intracranial Pressure, ICP Control and Glaucoma
Moderated by Suresh Viswanathan

10:30 – 11:00: John Berdahl: Intracranial Pressure in Glaucoma
11:00 – 11:10: Discussion and questions

11:10 – 11:50: Brian Samuels: CNS Control of Intraocular and Intracranial Pressure
11:50 – 12:00: Discussion and questions
State Ballroom:
• Noon – 1:00: **LUNCH** (opportunity to visit vendor exhibits)

Grand Ballroom: 1-1:05: Christopher J. Quinn, President, American Optometric Association

**Session 3: The Ocular Surface in Glaucoma and Implications for Glaucoma Surgery**
*Moderated by Danica Marrelli*

1:05 – 1:50: **Robert Fechtner (OGS Honoree Lecture): Ocular Surface Disease and Topical Glaucoma Therapy**
1:50 – 2:00: Discussion and questions

2:00 – 2:45: **John Berdahl: Minimally Invasive Glaucoma Surgery**
2:45 – 3:00: Discussion and questions

State Ballroom:
3:00 – 3:30: Afternoon Break (opportunity to visit vendor exhibits)

**Session 4: The Influences of Glaucoma on Quality of Life**
*Moderated by Thomas Freddo*

3:30 – 4:10: **Konrad Pesudovs: Quality of Life Issues for Glaucoma Patients**
4:10 – 4:20: Discussion and questions

4:20 – 4:40: **Robert Fechtner: Glaucoma in Developing Countries**
4:40 – 4:45: Discussion and questions

4:45 – 5:05: **David Friedman: Home Monitoring of Intraocular Pressure**
5:05 – 5:10: Discussion and questions

**Session 5: New Perspectives in Glaucoma Diagnosis, Glaucoma Surgery, Glaucoma’s Influence on Patients’ Quality of Life**
*Moderated by Murray Fingeret*

5:10 – 6:00: Panel discussion with all speakers

Red Lacquer Room:
6:30 - 9:30: Reception and Dinner

**Wednesday, October 11, 2017  OGS/AAO Joint Symposium**
*Moderated by Richard Madonna*

8:00-8:25 AM: **John Berdahl: Intracranial Pressure in Glaucoma**
8:25-8:30 AM: Discussion and questions

8:30-8:55 AM: **Robert Fechtner: Ocular Surface Disease and Glaucoma Therapy**
8:55-9:00 AM: Discussion and questions

9:00-9:25 AM: **David Friedman: Big Glaucoma Clinical Trials and their Key Lessons**
9:25-9:30 AM: Discussion and questions

9:30-9:40 AM: Panel Discussion
**Speakers**

**John Berdahl, MD**

John Berdahl, MD, is a partner at Vance Thompson Vision in Sioux Falls, SD where he specializes in advanced Refractive, Cataract, Corneal and Glaucoma Surgery. Dr. Berdahl serves on the Vision for Mars program and started a medical device company to help treat glaucoma and other diseases caused by an imbalance between intraocular pressure and intracranial pressure. His research interests include Cerebrospinal Fluid Pressure in Glaucoma, Minimally Invasive Glaucoma Surgery, Refractive Laser Assisted Cataract Surgery (ReLACS), Intraocular Lens Design and drug delivery, and he has published numerous book chapters and peer-reviewed articles. His commitment to those in need is demonstrated by his leadership role in EyeCare America and the numerous surgical mission trips he continues to participate in worldwide.

After graduating from Mayo Medical School, Dr. Berdahl completed his internship at the Mayo Clinic in Scottsdale, AZ and his residency at Duke University. He then went on the complete an anterior segment fellowship at Minnesota Eye Consultants. He has won numerous national awards including the Claes Dohlman Award from Harvard University and the Resident Writers Award. In 2013 he was named the top young physician in South Dakota and was recently named one of the Top 40 under 40 ophthalmologists worldwide in addition to the Top 40 under 40 business leaders in the Dakotas.

**Robert Fechtner, MD**

**The OGS Honoree**

Robert D. Fechtner, MD, is Professor and Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY. A New Jersey native, Dr. Fechtner is a graduate of the Accelerate Premedical-Medical Program at University of Michigan. He completed research fellowships in glaucoma at Tufts New England Medical Center and Albert Einstein College of Medicine, an ophthalmology residency at Montefiore Medical Center in New York and a glaucoma fellowship at University of California, San Diego under a Research Service Award from the NIH. He was most recently Professor and Director of the Glaucoma Division at Rutgers New Jersey Medical School before he relocated to Syracuse in 2016.

Dr. Fechtner is an active glaucoma clinician, surgeon and educator with a particular interest in glaucoma pharmacology and diagnostic technologies. He is the associate editor of the Textbook of Ocular Pharmacology and has published over 100 articles, book chapters and monographs.

Dr. Fechtner is an active member and of numerous national scientific and medical organizations including the American Glaucoma Society, the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the American Society of Cataract and Refractive Surgeons. Dr. Fechtner has served as the Executive Vice President of the World Glaucoma Association since 2012 and has organized the past three World Glaucoma Congresses.

**David Friedman, MD, MPH, PhD**

**President’s Lecturer**

David S. Friedman, MD, MPH, PhD is the Alfred Sommer Professor of Ophthalmology at the Wilmer Eye Institute of Johns Hopkins University School of Medicine and Professor in the Departments of Epidemiology and International Health at Johns Hopkins Bloomberg School of Public Health. Dr. Friedman is also the director of the Dana Center for Preventive Ophthalmology at Johns Hopkins. He graduated summa cum laude from Yale College, received his medical degree from Harvard Medical School, and obtained a PhD in
epidemiology from Johns Hopkins. He completed his residency at Wills Eye Hospital and served as a glaucoma fellow with Dr. Harry Quigley.

Dr. Friedman is the recipient of clinician scientist awards from the NIH, Research to Prevent Blindness and the American Geriatric Society. Since joining the Wilmer faculty in 1996 he has had continuous funding from the NIH, as well as numerous other funding organizations. He co-edited a definitive book on angle-closure glaucoma and has published nearly 300 peer-reviewed articles. He has served on the editorial boards of Ophthalmology, the Cochrane Collaboration, and the Journal of Glaucoma, and plays a leadership role in the World Glaucoma Association and the American Glaucoma Society. He also is the Senior Ophthalmologist for Helen Keller International, a large non-profit organization dedicated to alleviating blindness worldwide. He currently leads a CDC-funded program to identify novel approaches to screen underserved populations for eye diseases, especially glaucoma.

Dr. Friedman is world renowned for his contributions to the study of the mechanisms, epidemiology and prevention of angle-closure glaucoma. Over the last 20 years he has worked closely with researchers in Singapore, Guangzhou, Beijing and south India on this research. He identified novel dynamic risk factors for angle closure. This work formed the foundation for two seminal studies of angle closure glaucoma treatment including the EAGLE Trial and the Zhongshan Angle Closure Prevention (ZAP) Study. Dr. Friedman was a key member of the EAGLE Trial study team, a pivotal research study that demonstrated that early lens extraction is effective at treating angle-closure glaucoma. He is the co-principal investigator of the ZAP study which screened over 10,000 individuals in order to determine if prophylactic laser iridotomy is effective at preventing angle closure glaucoma. That study has completed seven years of follow-up and final results will be reported shortly.

In addition to his research, Dr. Friedman is listed on Best Doctors as a leading glaucoma specialist. Dr. Friedman also trains glaucoma fellows as well as residents. His dedication to teaching extends to the medical school where he is a co-director of the Scholarly Concentration program.

Konrad Pesudovs, BScOptom, PhD, MCOptom

Konrad Pesudovs PhD has been the Foundation Chair of Optometry and Vision Science at Flinders University since 2009. He completed his clinical training at the University of Melbourne (1990), his PhD at Flinders University (2000) before completing postdoctoral Fellowships in Bradford (UK) and Houston (USA). From 2004-2009 he ran the NHMRC Centre of Clinical Research Excellence in Ophthalmology Outcomes Research from the Department of Ophthalmology at Flinders University.

His research interest is ophthalmology outcomes research; incorporating optical, visual and patient-reported measurement into the holistic assessment of ophthalmic outcomes. A key element of this is the development of patient-reported outcome measures including visual disability, quality of life and other latent traits using Rasch analysis. He has developed a number of questionnaires and is the leader of an international project to develop item banking and computer adaptive testing for measuring patient-reported outcomes in ophthalmology (the Eye-tem Bank Project). Another key area of outcomes research is in the measurement of the optics of the eye and visual performance. He has conducted outcomes research in treatments for all the major blinding eye diseases, with particular emphasis on cataract and corneal disease. He also has a strong track record in health valuation and ophthalmic epidemiology particularly with the Global Burden of Disease Study.

He has published over 200 peer-reviewed papers, six book chapters, and over 40 other publications. He has made over 200 presentations at international conferences. His career grant funding is over US$9million. He sits on 3 journal editorial boards having previously sat on 5 others. He was Chairman of the Board of Administration of the National Vision Research Institute (2015-2016). He is a member of the Governing Council of the Australian College of Optometry (2010-), serving as President from 2016-. He has been a Committee Member of the Publications Committee for the Association for Research in Vision and Ophthalmology (2012-2014). He has won several international awards including the 2006 Waring Medal, 2008 Borish award, the 2009 and 2011 Garland Clay awards and shared The American Public Health Association Vision Care Section 2014 Outstanding Scientific Paper Award with the Vision Loss Expert Group of the Global Burden of Disease 2010.
Jack Phu, B. Optom, MPH
OGS 2016 Ezell Fellow
Jack Phu, B. Optom, MPH is currently a staff optometrist at Centre for Eye Health and is undertaking PhD studies in glaucoma and visual fields. He graduated from UNSW in 2011 and spent 3 years working in an independent private practice with a strong focus on ocular diseases. He became a Fellow of the American Academy of Optometry and completed a Masters in Public Health in 2014. He is involved in undergraduate teaching at UNSW in the areas of ocular diseases, clinical optometry and ocular therapeutics. He is also the 2016-2017 Optometric Glaucoma Society Ezell Fellow.

Lyne Racette, PhD
A native of Montreal (Canada), Dr. Racette completed her PhD in experimental psychology at Carleton University in Ottawa. After completing her postdoctoral fellowship at the University of California San Diego, she joined Indiana University in 2010 as an Assistant Professor. She is now an Associate Professor at the University of Alabama at Birmingham. She leads a research program focused on improving the detection of change in glaucoma. Her work has been funded by several foundations as well as by the National Institutes of Health. She has a long-standing interest in increasing diversity in science and is the outgoing Chair of the Diversity Initiatives Committee of the Association for Research in Vision and Ophthalmology.

Brian Samuels, MD, PhD
Brian Samuels received his undergraduate degree from Wabash College in 1997. Then he completed both his MD and PhD in medical neurobiology through the combined degree program at the Indiana University School of Medicine in 2004. After finishing ophthalmology residency at the University of Alabama in Birmingham (UAB), Brian completed a two-year clinical and research fellowship in glaucoma at the Duke Eye Center. He is an Associate Professor of Ophthalmology at UAB where he serves as the director of the glaucoma service and the glaucoma fellowship program. As a clinician-scientist, Brian enjoys the diversity of having a job that includes direct patient care, teaching fellows, residents and medical students, and running a basic science laboratory. His independent research interest involves understanding how differences between intraocular and intracranial pressure cause various optic neuropathies, including: glaucoma, idiopathic intracranial hypertension (IIH) and the vision impairment/intracranial pressure (VIIP) syndrome experienced by astronauts in microgravity. In addition to his independent work, he also enjoy working with collaborators who have synergistic research interests. Ultimately, he hopes that our preclinical scientific discoveries will translate into novel treatment options for patients with glaucoma and other blinding diseases. In his free time, Brian enjoys hiking, playing golf, and spending time with his wife, Anna and their two year old daughter, Tara.
This year’s WGC was held in Helsinki, Finland June 28-July 1 and the OGS continued its tradition of holding a Society Symposium on the first day of the meeting.

Our topic was “New Developments in Perimetry”, Murray Fingeret was the Program Chair. In this fast paced one-hour session, Jeffery Leibmann spoke on Central Field Testing in Glaucoma Detection; Alison McKendrick presented on modifications to the Central 24-2 Program and Anders Heijl discussed the development of Faster Testing Algorithms and Zeiss SITA Faster.

Mike Patella and Mike Chaglasian moderated a lively question and answer portion. Several OGS members were in attendance and made other presentations during the four day meeting. Travel Grants were once again awarded to members who were presenting.

Please put the 2019 WGC (Melbourne, Australia) on your calendar and join the OGS and the rest of the World Glaucoma Association in this unique international meeting.

Congratulations to the Optometric Glaucoma Society 2017 Ezell Fellow!

Nevin W. El-Nimri, OD, MS

Nevin El-Nimri is an optometrist currently working toward a PhD in Vision Science at the University of California, Berkeley. She completed her undergraduate training at UC Berkeley and returned there after earning her O.D. and Masters in Vision Science at The Ohio State University in 2014. The main focus of her current research is the mechanisms underlying the increased risk of glaucoma in myopes. As part of this research, she is investigating the efficacy of topical ocular hypotensive drugs as novel myopia control therapies that may also directly reduce the risk of glaucoma. Her research has a translational emphasis and involves both the guinea pig as an animal model for myopia and human subjects. Nevin is a fellow of the American Academy of Optometry and the recipient of the 2017 OGS Ezell Fellowship. She will be speaking at the 2018 OGS Annual Meeting in San Antonio, Texas.
Optometric Glaucoma Foundation

About Us
The Optometric Glaucoma Foundation is the philanthropic arm of the Optometric Glaucoma Society. The OGF is a newly-formed 501(c)3, not-for-profit organization.

Mission Statement
The mission of the Optometric Glaucoma Foundation is to support glaucoma education for the optometric profession. This includes supporting and developing educational programs for students, residents, educators and practitioners. The OGF will work with different groups to meet our goals including industry and educational institutions, as well as optometric and ophthalmologic organizations.

Officers
Murray Fingeret
President
Leo Semes
Vice President
John McSoley
Secretary
Austin Lifferth
Treasurer

Board of Directors
John Flanagan
Peter Lalle
Tom Lewis
Brian Mahoney
Ron Melton
Leslie O’Dell
C. Denise Pensyl
Robert Prouty

How to identify glaucomatous damage on Optical Coherence Tomography (OCT) scans.
Donald C. Hood, PhD
Columbia University, New York, NY

Friday, October 27, 2017

8:15am Welcome
8:30am 1. An Introduction and Background Material.
          2. The principles behind a method for diagnosing and understanding glaucomatous damage based upon OCT.
10:00am Morning Break
10:30am 3. How to use a one-page report to quickly diagnose and understand glaucomatous damage.
          4. Where can I find similar information in my commercial machine?
12:00pm Lunch
1:00pm 5. Understanding visual fields based upon OCT.
2:30 Afternoon Break
3:00pm 7. This is about a Method/Process not a Report.
          8. Case analysis, diagnostic tests, & review
4:30pm Adjournment
OGS Leadership and Committees

**Officers/Executive Committee**
- Michael Chaglasian – President
- Richard Madonna – Vice President
- Eric Schmidt – Treasurer
- Danica Marrelli – Secretary
- Ben Gaddie – Executive Vice President

**Past Presidents**
- Murray Fingeret 2001-2008
- John Flanagan 2008-2012
- Ben Gaddie 2012-2016

**Members at Large**
- Derek MacDonald
- Justin Schweitzer

**By-Laws**
- Daniel Roberts – Chair

**Industry Relations**
- Chris Lievens

**Nominating**
- John McSoley- Chair

**Membership & Recruitment**
- Mark Dunbar – Membership Co-Chair
- Tony Litwak – Recruiting – Co-Chair
- Barry Frauens
- Richard Madonna
- Trennda Rittenbach
- Justin Schweitzer
- Sarah Wood

**Program**
- Suresh Visvanathan – Chair
- Richard Madonna
- Leo Semes

**E-Journal / PCON Newsletter**
- Carl Jacobsen – Chair
- Scott Anthony
- Derek MacDonald
- Lisa Young

OGS Executive Committee
Anaheim, 2016
Founding Members
Paul Ajamian, OD
Jimmy D. Bartlett, OD, DOS, ScD
Richard Bennett, OD
Michael Chaglasian, OD
George Comer, OD
Shaban Demirel, OD, PhD
Mark Dunbar, OD
David Evans, PhD
Murray Fingeret, OD
John Flanagan, McOptom, PhD
Brad Fortune OD, PhD
Ben Gaddie, OD
William A Hare OD, PhD
Ronald Harwerth, PhD
Chris Johnson, PhD
Peter Lalle, OD
Tom Lewis, OD, PhD
Tony Litwak, OD
Vic Malinovsky
John McSoley, OD
Ron Melton, OD
Vincent Michael Patella, OD
Bruce Onofrey
Robert Prouty, OD
Chris Quinn, OD
Daniel Roberts, OD, MS
Pam Sample, PhD
Leo Semes, OD
Joseph Sowka, OD
William Swanson, PhD
James Thimons, OD
Randall Thomas, OD
Robert P. Wooldridge, OD

In Memoriam
Larry J. Alexander, OD
Thom J. Zimmerman, MD, PhD

OGS Ezell Fellows
2017 Nevin W. El-Nimri, OD, MS
2016 Jack Phu, BOptom, MPH
2015 Lakshmi Priya Rajagopalan, BS, PhD
2013 Kevin Ivers, OD, PhD
2012 Kevin Ivers, OD, PhD
2011 Nimesh Patel, OD, PhD
2010 Nimesh Patel, OD, PhD
2008 Joe Wheat, OD, PhD

Founders Award
2016 Gerhard Zinser, PhD
2015 Harry A. Quigley, MD
2012 Robert N. Weinreb, MD
2011 Douglas R. Anderson, MD

Distinguished Service Award
2016 Ben Gaddie, OD
2013 John G. Flanagan, MCOptom, PhD
2012 Louis J. Catania, OD
2011 Tom L. Lewis, OD, PhD
2010 V. Michael Patella, OD
2008 Murray Fingeret, OD

Research Excellence Award
2014 Donald Hood, PhD
2013 Ronald S. Harwerth, OD, PhD
2009 Sir Peng Tee Khaw, MD, FRCOphth

Corporate Partnership Award
2016 Rick Halprin
2013 Richard D. Bay
<table>
<thead>
<tr>
<th>Dates</th>
<th>Location</th>
<th>President’s Lecturer</th>
<th>OGS Honoree</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 9-11, 2017</td>
<td>Chicago, IL</td>
<td>David Friedman, MD, MPH, PhD</td>
<td>Robert Fechtner, MD</td>
</tr>
<tr>
<td>November 7-9, 2016</td>
<td>Anaheim, CA</td>
<td>Felipe A. Medeiros, MD, PhD</td>
<td>George A. Cioffi, MD</td>
</tr>
<tr>
<td>October 5-7, 2015</td>
<td>New Orleans, LA</td>
<td>Jonathan S. Myers, MD</td>
<td>Mae Gordon, PhD</td>
</tr>
<tr>
<td>November 10-12, 2014</td>
<td>Denver, CO</td>
<td>Steven L. Mansberger, MD, MPH</td>
<td>David Garway-Heath, MD</td>
</tr>
<tr>
<td>October 22-23, 2013</td>
<td>Seattle, WA</td>
<td>Anthony Realini, MD, MPH</td>
<td>Claude Burgoyne, MD</td>
</tr>
<tr>
<td>October 23-24, 2012</td>
<td>Phoenix, AZ</td>
<td>Brad Fortune, OD, PhD</td>
<td>Jost Jonas, MD</td>
</tr>
<tr>
<td>October 11-12, 2011</td>
<td>Boston, MA</td>
<td>Keith Martin, MD, FRCOphth</td>
<td>Jeffrey Liebmann, MD</td>
</tr>
<tr>
<td>November 15-16, 2010</td>
<td>San Francisco, CA</td>
<td>Kuldev Singh, MD, MPH</td>
<td>Wallace L.M. Alward, MD</td>
</tr>
<tr>
<td>November 9-11, 2009</td>
<td>Orlando, FL</td>
<td>Christopher A. Girkin, MD</td>
<td>George L. Spaeth, MD</td>
</tr>
<tr>
<td>October 20-22, 2008</td>
<td>Anaheim, CA</td>
<td>Theodore Krupin, MD</td>
<td>Robert Ritch, MD</td>
</tr>
<tr>
<td>October 22-23, 2007</td>
<td>Tampa, FL</td>
<td>David Greenfield, MD</td>
<td>Paul Kaufman, MD</td>
</tr>
<tr>
<td>December 5-6, 2006</td>
<td>Denver, CO</td>
<td>Balwantray Chauhan, PhD</td>
<td>Harry Quigley, MD</td>
</tr>
<tr>
<td>December 7, 2005</td>
<td>San Diego, CA</td>
<td></td>
<td>Stephen Drance, OC, MD</td>
</tr>
<tr>
<td>December 8, 2004</td>
<td>Tampa, FL</td>
<td></td>
<td>Douglas R. Anderson, MD</td>
</tr>
<tr>
<td>December 9, 2003</td>
<td>Dallas, TX</td>
<td></td>
<td>Anders Heijl, MD</td>
</tr>
<tr>
<td>December 11, 2002</td>
<td>San Diego, CA</td>
<td></td>
<td>Robert N. Weinreb, MD</td>
</tr>
</tbody>
</table>
Welcome New OGS Members

Jennifer Gould, OD, MS, FAAO
SUNY College of Optometry
New York, NY

Brian Mahoney, OD, FAAO
Department of Veterans Affairs
Wilmington, DE

John O’Donnell, OD
Premier Eye Care Group
Harrisburg, PA

Andrew Rixon, OD, FAAO
Department of Veterans Affairs
Memphis, TN

Jessica Steen, OD, FAAO, Dipl. ABO
Nova Southeastern University College of Optometry
Fort Lauderdale, FL
For newly diagnosed patients with elevated IOP

Power from the start.
Foundation for the journey.

Sustained 30% IOP lowering at 12, 14, and 20 hours postdose in a 3-month study**

TRAVATAN Z® (travoprost ophthalmic solution) 0.004%

INDICATIONS AND USAGE
TRAVATAN Z® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Dosage and Administration
The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® Solution should not be administered more than once daily dose. It has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.

TRAVATAN Z® Solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the brands should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions
Pigmentation—Transport ophthalmic solutions have been reported to increase the pigmentation of the iris, perilimbal tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as transport is administered. After discontinuation of transport, pigmentation of the iris is likely to be permanent, while pigmentation of the perilimbal tissue and eyelash changes have been reported to be reversible in some patients. The long-term effects of increased pigmentation are not known. While treatment with TRAVATAN Z® Solution can be continued in patients who develop minimally increased iris pigmentation, these patients should be examined regularly.

Eyelash Changes—TRAVATAN Z® Solution may gradually change eyelash and eyelid hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.

Anterior Inflammation—TRAVATAN Z® Solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Muscarinergic Side Effects—Muscarinergic side effects, including ocular miosis, has been reported during treatment with transport ophthalmic solution, TRAVATAN Z® Solution should be used with caution in aphakic patients. Pre-existing patients with a torn posterior lens capsule, or in patients with known risk factors for muscarinic side effects.

Angina-chest, inflammatory, or nonspecific ocular symptoms—TRAVATAN Z® Solution has not been evaluated for the treatment of angina-chest, inflammatory, or nonspecific ocular symptoms.

Bacterial Contamination—There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Use With Contact Lenses—Contact lenses should be removed prior to instillation of TRAVATAN Z® Solution and may be reintroduced 15 minutes following its administration.

Adverse Reactions
The most common adverse reaction observed in clinical studies with TRAVATAN Z® Solution was ocular hyperemia, which was reported in 30 to 50% of patients. Up to 5% of patients discontinued therapy due to conjunctival hyperemia. Conjunctival reactions were reported at an incidence of 5 to 10% in those clinical studies included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus. In postmarketing use with prostaglandin analogs, perilimbal and lid changes including thickening of the eyelid margins have been observed.

Use in Specific Populations
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

For additional information on TRAVATAN Z® Solution, please refer to the Brief Summary of Prescribing Information on the following page.

© 2017 Novartis

Start with BAK-free TRAVATAN Z® Solution
Meet the VISION aerieS

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye.

See the future of eye care with Aerie.
www.aeriepharma.com

The gold standard is about to get...

Faster!
Stay tuned for the latest innovation in Perimetry.

Come see us in the exhibition hall.
ZEISS is a proud supporter of the Optometric Glaucoma Society.
Optometric Glaucoma Society
17th Annual Meeting
November 5-7, 2018
San Antonio, TX

optometricglaucomasociety.org